BRKR BRUKER CORP
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1109354 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.2%
TTM net income YoY-490.4%
TTM EPS YoY-587.5%
Revenue 3-yr CAGR7.6%
Net income 3-yr CAGR—
Margins
Gross margin47.7%
Operating margin-2.0%
Net margin-3.5%
FCF margin7.0%
EBITDA margin4.5%
Returns
ROE-5.2%
ROA-2.0%
ROIC (approx.)-1.4%
Asset turnover0.57x
Leverage & solvency
Liabilities / assets59.8%
Debt / equity0.74x
Current ratio1.84x
Interest coverage-1.23x
Cash quality & payout
Operating cash flow / net income-2.77x
Accruals ratio-7.6%
Payout ratio—
Capex / revenue2.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.44B | $3.37B |
| Cost of revenue | $1.86B | $1.72B |
| Gross profit | $1.58B | $1.65B |
| R&D expense | $395.20M | $376.50M |
| SG&A expense | $946.50M | $893.80M |
| Operating income | $68.20M | $253.10M |
| Interest expense | $60.30M | $47.90M |
| Pretax income | $22.00M | $206.90M |
| Income tax | $29.30M | $91.40M |
| Net income | -$8.60M | $113.10M |
| EBITDA | $288.50M | $436.90M |
| EPS (basic) | -0.15 | 0.76 |
| EPS (diluted) | -0.15 | 0.76 |
| Dividends declared per share | — | 0.20 |
| Weighted avg. shares (diluted) | 151.80M | 149.50M |
| Balance sheet | ||
| Cash & equivalents | $298.80M | $186.70M |
| Receivables | $544.90M | $565.50M |
| Inventory | $1.09B | $1.07B |
| Current assets | $2.21B | $2.05B |
| PP&E, net | $744.80M | $669.30M |
| Goodwill | $1.55B | $1.51B |
| Intangibles | $899.60M | $912.50M |
| Total assets | $6.24B | $5.81B |
| Current liabilities | $1.28B | $1.28B |
| Short-term debt | $16.60M | $32.50M |
| Long-term debt | $1.85B | $2.06B |
| Total debt | $1.87B | $2.09B |
| Total liabilities | $3.73B | $3.99B |
| Shareholders' equity | $2.46B | $1.78B |
| Net debt | $1.57B | $1.91B |
| Shares outstanding | 152.14M | 151.68M |
| Cash flow statement | ||
| Operating cash flow | $134.10M | $251.30M |
| Capital expenditure | $90.80M | $115.30M |
| Free cash flow | $43.30M | $136.00M |
| Investing cash flow | -$196.50M | -$1.76B |
| Financing cash flow | $135.10M | $1.23B |
| Depreciation & amortization | $220.30M | $183.80M |
| Stock-based compensation | $20.20M | $25.30M |
| Dividends paid | $22.80M | $30.20M |
| Share buybacks | $10.00M | $0 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.